



VGI Health Technology Limited

ABN: 35 111 082 485

Address: Suite 4, 24 Birdwood Lane, Lane Cove,

NSW 2066 Australia

www.vgiht.com | Tel: +61 2 8279 8908

## Notice of Share Consolidation

**Sydney, New South Wales, 28 November 2025** – VGI Health Technology Limited (**NSX:VTL**) is pleased to advise that at the Annual General Meeting held today, shareholders approved the resolution to consolidate the issued capital of the Company on a 1 for 10 basis (**Consolidation**).

The Consolidation will have the effect of decreasing the VTL Shares on issue to approximately 14,629,725 Shares. As the Consolidation applies equally to all shareholders, the Consolidation will have no material effect on the percentage interest of each individual shareholder.

Where a fractional entitlement arises to a share, the Company will round the fraction down to the nearest whole number.

The Consolidation will take effect in accordance with the below timetable:

Date	Event
Friday 28 November 2025	Meeting to approve the Consolidation and issue Shares pursuant to Resolutions 2, 3 and 4
Friday 28 November 2025 (Day 0)	Announcement about Consolidation
Thursday 18 December 2025 (Day 10)	Ex-Date
Friday 19 December 2025 (Day 11)	Record Date
Monday 22 December 2025	Completion Date

Note: the timetable is subject to change in accordance with the Listing Rules and applicable laws.

Authorised for release by the Board of Directors.

For more information please contact:

**Dr Glenn Tong**, CEO and Managing Director  
Ph: +61 (0) 412 193 350

**Catriona Glover**, Company Secretary  
Ph: +61 (0) 402 328 200

---

## About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence- based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:  
[https://www.nsx.com.au/broker\\_list\\_print.asp](https://www.nsx.com.au/broker_list_print.asp)